

Emily B Ehlerding

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6773617/emily-b-ehlerding-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35
papers

1,475
citations

20
h-index

38
g-index

39
ext. papers

1,876
ext. citations

8.9
avg, IF

4.99
L-index

#	Paper	IF	Citations
35	Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics. <i>Molecular Pharmaceutics</i> , 2020 , 17, 1697-1705	5.6	12
34	A Melanin-Based Natural Antioxidant Defense Nanosystem for Theranostic Application in Acute Kidney Injury. <i>Advanced Functional Materials</i> , 2019 , 29, 1904833	15.6	65
33	Aptamer-Conjugated Framework Nucleic Acids for the Repair of Cerebral Ischemia-Reperfusion Injury. <i>Nano Letters</i> , 2019 , 19, 7334-7341	11.5	31
32	Site-Specific Immuno-PET Tracer to Image PD-L1. <i>Molecular Pharmaceutics</i> , 2019 , 16, 2028-2036	5.6	24
31	Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with Zr-Df-Atezolizumab. <i>Bioconjugate Chemistry</i> , 2019 , 30, 1434-1441	6.3	20
30	Molecular imaging of β cells: diabetes and beyond. <i>Advanced Drug Delivery Reviews</i> , 2019 , 139, 16-31	18.5	21
29	Multimodality Imaging Agents with PET as the Fundamental Pillar. <i>Angewandte Chemie - International Edition</i> , 2019 , 58, 2570-2579	16.4	40
28	Multimodale Kontrastmittel für die kombinierte Positronenemissionstomographie. <i>Angewandte Chemie</i> , 2019 , 131, 2592-2602	3.6	3
27	Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models. <i>American Journal of Cancer Research</i> , 2019 , 9, 53-63	4.4	18
26	Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection. <i>American Journal of Cancer Research</i> , 2019 , 9, 1454-1468	4.4	10
25	ImmunoPET imaging of CD38 expression in hepatocellular carcinoma using Cu-labeled daratumumab. <i>American Journal of Translational Research (discontinued)</i> , 2019 , 11, 6007-6015	3	7
24	CD146-Targeted Multimodal Image-Guided Photoimmunotherapy of Melanoma. <i>Advanced Science</i> , 2019 , 6, 1801237	13.6	28
23	Antibody-Based Tracers for PET/SPECT Imaging of Chronic Inflammatory Diseases. <i>ChemBioChem</i> , 2019 , 20, 422-436	3.8	13
22	Dual-Targeted Molecular Imaging of Cancer. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 390-395	8.9	20
21	Noninvasive PET Imaging of T cells. <i>Trends in Cancer</i> , 2018 , 4, 359-373	12.5	63
20	Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models. <i>Molecular Pharmaceutics</i> , 2018 , 15, 1627-1634	5.6	11
19	PET and SPECT imaging of melanoma: the state of the art. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 132-150	8.8	16

18	Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 110-120	8.8	73
17	Targeting angiogenesis for radioimmunotherapy with a Lu-labeled antibody. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 123-131	8.8	15
16	PET Imaging of Receptor Tyrosine Kinases in Cancer. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 1625-1636	6.1	27
15	Chelator-Free Radiolabeling of Nanographene: Breaking the Stereotype of Chelation. <i>Angewandte Chemie</i> , 2017 , 129, 2935-2938	3.6	9
14	Chelator-Free Radiolabeling of Nanographene: Breaking the Stereotype of Chelation. <i>Angewandte Chemie - International Edition</i> , 2017 , 56, 2889-2892	16.4	53
13	CD38 as a PET Imaging Target in Lung Cancer. <i>Molecular Pharmaceutics</i> , 2017 , 14, 2400-2406	5.6	17
12	Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1296-1305	8.8	23
11	ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. <i>Molecular Pharmaceutics</i> , 2017 , 14, 1782-1789	5.6	62
10	Chelator-Free Labeling of Metal Oxide Nanostructures with Zirconium-89 for Positron Emission Tomography Imaging. <i>ACS Nano</i> , 2017 , 11, 12193-12201	16.7	27
9	Preclinical Pharmacokinetics and Biodistribution Studies of ⁸⁹ Zr-Labeled Pembrolizumab. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 162-168	8.9	110
8	CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody. <i>Theranostics</i> , 2016 , 6, 1918-33	12.1	46
7	Harnessing the Power of Molecular Imaging for Precision Medicine. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 171-2	8.9	6
6	Smaller Agents for Larger Therapeutic Indices: Nanoscale Brachytherapy with ¹⁷⁷ Lu-Labeled Gold Nanoparticles. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 834-5	8.9	4
5	NanoLuc: A Small Luciferase Is Brightening Up the Field of Bioluminescence. <i>Bioconjugate Chemistry</i> , 2016 , 27, 1175-1187	6.3	202
4	Imaging the Biodistribution and Performance of Transplanted Stem Cells with PET. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1331-2	8.9	3
3	Molecular Imaging of Immunotherapy Targets in Cancer. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1487-1492	6.9	65
2	In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine. <i>ACS Nano</i> , 2015 , 9, 3926-34	16.7	137
1	Theranostic nanoparticles. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1919-22	8.9	173

